In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...

University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...

The loans can be converted to stock if certain milestones are reached, or Moderna is required to pay investors back by 2032.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

Precision Medicine Group sells clinical research and commercialization services to biopharmaceutical companies, including biomarker-driven R&D.